Emcure Pharma shares rally 10% to 52-week high on hiking FY27 revenue guidance; check Q2 numbers

The company witnessed broad-based growth in its revenue, profitability and earnings, and expects to sustain its business momentum in the second half of the current fiscal year (H2 FY27). Furthermore, analysts took note of the company increasing its revenue growth guidance to over 20% for FY27.

It posted a 34% year-on-year (YoY) surge in its consolidated net profit to ₹326 crore, compared with ₹243 crore clocked in the corresponding period of the preceding fiscal year.

Its consolidated revenue from operations advanced 24% YoY to ₹2,820 crore during the quarter under review, as against ₹2,270 crore in the July-September quarter of the 2025-26 fiscal year (Q2 FY26).

At an operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹588 crore in the quarter ended September 30, 2026, registering a surge of 24% YoY from ₹475 crore in the year-ago period.

Its EBITDA margin remained almost flat at 20.84% for the reporting quarter, in contrast to 20.9% in Q2 FY26.

Key highlights

The domestic market contributed 41% to the pharmaceutical firm’s revenue, followed by the rest of the world (RoW) at 22.3%, the European market at 21.4%, and the Canadian market at 15.3%, as per its investor presentation.

The domestic market sustained double-digit YoY growth for the second consecutive quarter, improving from 10% in Q1 FY27 to 12% in Q2 FY27, led by the women’s health franchise, cardio-metabolics and the CNS range, supported by improved traction in Poviztra.

It saw strong delivery across the UK and the European Union (EU), led by base business execution and new product launches. Furthermore, the product pipeline has given visibility for sustained medium-term growth in Europe.

Its Canada business posted healthy growth via market share gains and recent launches, with balanced growth across Quebec and the rest of Canada.

What analysts said

Emcure Pharma share performance

At around 11:38 AM, the stock was trading at ₹2,170.90 per equity share, up by 9.83%. The scrip reached a year’s low of ₹1,306.50 per unit on November 4, 2025.

The scrip has soared 16% in the past week and 12% over the month. On a year-to-date (YTD) basis, it has surged 59%.

Emcure Pharmaceuticals has a total market capitalisation of ₹41,246.89 crore as of November 4, 2026, according to data on the NSE.